SG11201806348PA - Steroid derivative fxr agonist - Google Patents

Steroid derivative fxr agonist

Info

Publication number
SG11201806348PA
SG11201806348PA SG11201806348PA SG11201806348PA SG11201806348PA SG 11201806348P A SG11201806348P A SG 11201806348PA SG 11201806348P A SG11201806348P A SG 11201806348PA SG 11201806348P A SG11201806348P A SG 11201806348PA SG 11201806348P A SG11201806348P A SG 11201806348PA
Authority
SG
Singapore
Prior art keywords
fxr agonist
steroid derivative
derivative fxr
relates
steroid
Prior art date
Application number
SG11201806348PA
Inventor
Haiying He
Hualing Xiao
Peng Li
Chunyan Du
Zhi Luo
Shuhui Chen
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of SG11201806348PA publication Critical patent/SG11201806348PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a compound represented by formula (I), a tautomer thereof a acceptable thereof, relates applications thereof in the preparation of drugs for treating FXR related diseases.
SG11201806348PA 2016-01-28 2017-01-25 Steroid derivative fxr agonist SG11201806348PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610061293 2016-01-28
CN201610331759 2016-05-18
PCT/CN2017/072567 WO2017129125A1 (en) 2016-01-28 2017-01-25 Steroid derivative fxr agonist

Publications (1)

Publication Number Publication Date
SG11201806348PA true SG11201806348PA (en) 2018-08-30

Family

ID=59397430

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201806348PA SG11201806348PA (en) 2016-01-28 2017-01-25 Steroid derivative fxr agonist
SG10201913768TA SG10201913768TA (en) 2016-01-28 2017-01-25 Steroid derivative fxr agonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913768TA SG10201913768TA (en) 2016-01-28 2017-01-25 Steroid derivative fxr agonist

Country Status (15)

Country Link
US (2) US10875888B2 (en)
EP (1) EP3409684B1 (en)
JP (1) JP6924765B2 (en)
KR (1) KR20180100703A (en)
CN (1) CN109071593B (en)
AU (2) AU2017213032B2 (en)
CA (1) CA3012396C (en)
CL (1) CL2018002009A1 (en)
IL (1) IL260795B (en)
MX (1) MX2018009175A (en)
MY (1) MY196292A (en)
PH (1) PH12018550120A1 (en)
SG (2) SG11201806348PA (en)
WO (1) WO2017129125A1 (en)
ZA (1) ZA201805231B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017118569A (en) 2014-11-06 2018-12-06 Энанта Фармасьютикалс, Инк. BILIC ACID ANALOGUES AS FXR / TGR5 AGONISTS AND WAYS OF THEIR APPLICATION
WO2016086169A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
SG11201706089RA (en) 2015-02-11 2017-09-28 Enanta Pharm Inc Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
CN107427527B (en) 2015-03-31 2021-01-26 英安塔制药有限公司 Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
MY196292A (en) * 2016-01-28 2023-03-24 Chia Tai Tianqing Pharmaceutical Group Co Ltd Steroid Derivative Fxr Agonist
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2018102418A1 (en) 2016-11-29 2018-06-07 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
EP3606533B1 (en) 2017-04-07 2023-11-15 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
CN109134572A (en) * 2017-06-19 2019-01-04 中国科学院上海药物研究所 Chlolic acid derivatives and its preparation method and application
JP7244487B2 (en) * 2017-07-26 2023-03-22 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Crystalline or amorphous steroidal derivative FXR agonist, its preparation method and use
EP3660030A4 (en) * 2017-07-26 2021-04-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for preparing steroid derivative fxr agonist
CN107383139A (en) * 2017-08-09 2017-11-24 杭州和泽医药科技有限公司 The method that a kind of β cholanic acid new derivatives of 7 oxo of 3 α hydroxyls 5 prepare shellfish cholic acid difficult to understand
US11111265B2 (en) * 2017-11-02 2021-09-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for preparing cholic acid compound
CN107722000A (en) * 2017-11-03 2018-02-23 中国药科大学 The preparation of the berberinc derivate of 9-substitution and its medical usage
CN107987116B (en) * 2018-01-17 2021-01-05 中国药科大学 Chenodeoxycholic acid derivatives, preparation method and medical application thereof
CN111285914B (en) * 2018-12-10 2023-02-17 江西青峰药业有限公司 Preparation method of obeticholic acid
MX2022000742A (en) 2019-07-18 2022-02-14 Enyo Pharma Method for decreasing adverse-effects of interferon.
CN110878113B (en) * 2019-11-07 2021-02-02 成都贝诺科成生物科技有限公司 Cholic acid derivative with antibacterial activity and medicinal composition thereof
EP4090327A1 (en) 2020-01-15 2022-11-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of fxr agonists for treating an infection by hepatitis d virus
CN117202905A (en) 2021-01-14 2023-12-08 埃尼奥制药公司 Synergistic effects of FXR agonist and IFN for the treatment of HBV infection
JP2024517181A (en) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ Strong enhancement of the effects of TLR3 agonists using FXR agonists as combination therapy
CN113861258A (en) * 2021-09-05 2021-12-31 中国海洋大学 Method for synthesizing sargasterol
WO2023048528A1 (en) * 2021-09-24 2023-03-30 (주)샤페론 Pharmaceutical composition comprising inflammasome inhibitor as active ingredient for prevention, alleviation, or treatment of atopic dermatitis
KR20230043773A (en) * 2021-09-24 2023-03-31 (주)샤페론 Pharmaceutical composition for preventing, improving or treating non-alcoholic steatohepatitis, liver fibrosis comprising inflammasome inhibitor compound as an active ingredient
WO2023233346A1 (en) * 2022-06-01 2023-12-07 Precision Bio-Therapeutics S.R.L. Cholesterol derivatives and their uses
CN116497082B (en) * 2023-06-27 2023-09-29 华南理工大学 Method for synthesizing 3 alpha, 7 alpha, 24R-trihydroxy cholesterol by chemical-enzymatic method

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140079B1 (en) 1998-12-23 2009-06-03 Glaxo Group Limited Assays for ligands for nuclear receptors
JP4021327B2 (en) 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Steroids as agonists for FXR
EP1568706A1 (en) * 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
AU2013256362A1 (en) * 2012-05-01 2014-11-13 Catabasis Pharmaceuticals, Inc. Fatty acid conjugates of statin and FXR agonists: compositions and methods of use
US10458891B2 (en) * 2014-08-20 2019-10-29 Hoffmann-La Roche Inc. In vitro method and apparatus for analysing the behaviour of substances in simulated physiological environment
WO2016086169A1 (en) * 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2016086134A1 (en) * 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) * 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CN107427527B (en) * 2015-03-31 2021-01-26 英安塔制药有限公司 Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CN107250150B (en) 2015-04-28 2019-11-22 江苏豪森药业集团有限公司 Chlolic acid derivatives and preparation method thereof and medical usage
CN106083978A (en) 2015-04-28 2016-11-09 上海迪诺医药科技有限公司 Sulfonyl amino carbonyl derivant, its pharmaceutical composition and application
MY196292A (en) * 2016-01-28 2023-03-24 Chia Tai Tianqing Pharmaceutical Group Co Ltd Steroid Derivative Fxr Agonist
US10323060B2 (en) * 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
EP3436316A4 (en) * 2016-03-31 2020-03-04 B/E Aerospace, Inc. System and methods for protecting a passenger in an oblique-mounted aircraft seat

Also Published As

Publication number Publication date
MY196292A (en) 2023-03-24
ZA201805231B (en) 2022-03-30
MX2018009175A (en) 2018-11-29
CN109071593A (en) 2018-12-21
US20190382437A1 (en) 2019-12-19
AU2017213032B2 (en) 2021-01-07
EP3409684A1 (en) 2018-12-05
AU2021202018B2 (en) 2022-04-07
JP6924765B2 (en) 2021-08-25
IL260795B (en) 2021-04-29
AU2017213032A1 (en) 2018-08-30
US10875888B2 (en) 2020-12-29
CA3012396A1 (en) 2017-08-03
WO2017129125A1 (en) 2017-08-03
JP2019503392A (en) 2019-02-07
US11667667B2 (en) 2023-06-06
BR112018015474A2 (en) 2018-12-18
CA3012396C (en) 2024-03-26
CL2018002009A1 (en) 2018-11-05
EP3409684B1 (en) 2024-01-03
AU2021202018A1 (en) 2021-04-29
KR20180100703A (en) 2018-09-11
CN109071593B (en) 2021-01-15
SG10201913768TA (en) 2020-03-30
EP3409684A4 (en) 2019-10-09
PH12018550120A1 (en) 2019-03-18
US20210040140A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
SG11201806348PA (en) Steroid derivative fxr agonist
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12018502516B1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
TN2018000239A1 (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12019500480A1 (en) Pyridine compound
TW201613911A (en) Heterocyclic compounds and uses thereof
MX2016013689A (en) 4-amino-imidazoquinoline compounds.
MY197698A (en) Oxysterols and methods of use thereof
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
EA201791304A1 (en) IZOHINOLINA DERIVATIVES FOR HIV TREATMENT
JOP20170101B1 (en) SYNTHESIS of INDAZOLES
PH12019501955A1 (en) Tri-cycle compound and applications thereof
PH12016502246A1 (en) Carboxamide derivatives
MX2016014946A (en) Carboxamide derivatives.
JOP20200030A1 (en) Pentacyclic compound
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
MX2018016339A (en) Anti-infective heterocyclic compounds and uses thereof.
MX2017008074A (en) IMIDAZOPYRIDAZINE DERIVATIVES AS PI3Kß INHIBITORS.
MX2017008076A (en) Heterocyclyl linked imidazopyridazine derivatives as pi3kbeta inhibitors.
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
EA038580B9 (en) Steroid derivative fxr agonist
MY190171A (en) Synthesis of indazoles